Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience

Who's speaking

• Dr. Sophia Skermorn — guest

Chapters

• 0:00Cisplatin Retreatment in Relapsed Hepatoblastoma — Dr. Skermorn presents institutional data on salvage therapy for relapsed/refractory hepatoblastoma, highlighting survival differences between cisplatin-based and non-cisplatin regimens and the role of aggressive surgical management.

Key claims

• 0:12There is no established standard salvage therapy regimen for relapsed hepatoblastoma — Dr. Sophia Skermorn
• 0:17The Cincinnati Children's retrospective review of 30 patients represents one of the largest published cohorts evaluating patients with refractory or recurrent hepatoblastoma — Dr. Sophia Skermorn
• 0:25The overall survival for the cohort was about 50% — Dr. Sophia Skermorn
• 0:28Children who received cisplatin as part of their salvage therapy had survival of about 80% compared to 25% for those who did not receive cisplatin — Dr. Sophia Skermorn
• 0:36The improved survival outcomes with cisplatin may be due to persistent platinum sensitivity or better tumor biology rather than proving causality — Dr. Sophia Skermorn
• 0:49Most patients underwent additional surgery as part of their salvage therapy, either liver resection, liver transplant, or pulmonary metastasectomy — Dr. Sophia Skermorn
• 0:57Salvage therapy for relapsed hepatoblastoma is multimodal — Dr. Sophia Skermorn
• 0:59Cisplatin retreatment should be balanced with the risk of cumulative toxicity — Dr. Sophia Skermorn

Open questions

• Does cisplatin retreatment directly cause improved survival or does it reflect selection of patients with more favorable tumor biology?
• What is the optimal balance between potential survival benefit and cumulative cisplatin toxicity in salvage therapy?